A Herald of Plasma Cell Myeloma: A Report of Malignant Plasma Cells Identified in Parathyroid Adenoma and a Review of Non-parathyroid Malignancies in Parathyroid Glands.
Cracolici V et al. Head Neck Pathol. 2017 Oct 13. doi: 10.1007/s12105-017-0861-7. [Epub ahead of print].

Multiple Myeloma Presenting with Autoimmune Autonomic Ganglionopathy.
Nakae Y et al. Intern Med. 2017 Oct 11. doi: 10.2169/internalmedicine.9096-17. [Epub ahead of print].

Clinical features of multiple myeloma patients with isolated extramedullary relapse.
Qu XY et al. J Biomed Res. 2017 Sep 30. doi: 10.7555/JBR.31.20140090. [Epub ahead of print].

Heart and Lung Complications: Assessment and Prevention of Venous Thromboembolism and Cardiovascular Disease in Patients With Multiple Myeloma
.
Noonan K et al. Clin J Oncol Nurs. 2017 Oct 1;21(5):37-46. doi: 10.1188/17.CJON.S5.37-46.

Myelosuppression, Bone Disease, and Acute Renal Failure: Evidence-Based Recommendations for Oncologic Emergencies. Bridle K et al. Clin J Oncol Nurs. 2017 Oct 1;21(5):60-76. doi: 10.1188/17.CJON.S5.60-76.

Lenalidomide-Associated Thyroid-Related Eyelid Retraction.
Slean GR et al. Ophthal Plast Reconstr Surg. 2017 Oct 19. doi: 10.1097/IOP.0000000000001012. [Epub ahead of print].

Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
Fradley MG et al. Br J Haematol. 2017 Oct 19. doi: 10.1111/bjh.14970. [Epub ahead of print].

Pituitary plasmacytoma-a rare presentation of multiple myeloma.
Comerford CM et al. Ir J Med Sci. 2017 Oct 18. doi: 10.1007/s11845-017-1690-0. [Epub ahead of print].